BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 27, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 6/24 cls
Adventrx Pharmaceuticals Inc. (NYSE-A:ANX) Rodman Michael Higgins Price target Market outperform 20% $2.85
Higgins raised his target to $16 from $4.50, saying investors are overlooking the value of Adventrx's sickle cell disease candidate ANX-188 (formerly poloxamer 188), a non-ionic block copolymer surfactant. He estimates ANX-188 revenue of $115M in 2018. ANX-188 has Orphan Drug designation for sickle cell crisis in pediatric patients and has also been studied in a Phase III trial in patients with sickle cell disease in acute vaso-occlusive crisis. The company plans to start a...

Read the full 650 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >